Intelligence · Clinical Development
Pipeline search results
Programs matching “doxorubicin” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 24 pipeline programs matching "doxorubicin" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
BOOG 2010-02 Stop&Go study
Teva Pharma GmbH
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1 trial -
Doxorubicin
Takeda
Hodgkin Lymphoma
1 trial -
Doxorubicine + docetaxel sequential
Sanofi Pasteur
Breast Neoplasms
1 trial -
doxorubicin hydrochloride
Children's Hospital of Fudan University
Adult Alveolar Soft-part Sarcoma
1 trial -
doxorubicin hydrochloride
United Therapeutics Europe Ltd
Stage III Bladder Cancer
1 trial -
doxorubicin in combination with palifosfamide-tris
Alaunos Therapeutics
Soft Tissue Sarcoma
1 trial -
non-pegylated liposomal doxorubicin
Teva Pharma GmbH
Tubular Breast Cancer Stage II
1 trial -
Anlotinib+ Liposomal Doxorubicin
The First People's Hospital of Lianyungang
Sarcoma
1 trial -
Cisplatin and Doxorubicin
Chinese University of Hong Kong
Gastric Cancer Peritoneal Metastases
1 trial -
Cyclophosphamide Doxorubicin Vincristine Lamivudine
Taiwan Liposome Company
Non-Hodgkin's Lymphoma
1 trial -
Doxorubicin Hydrochloride
Children's Hospital of Fudan University
Childhood Renal Cell Carcinoma
1 trial -
Doxorubicin liposome
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Liposomal doxorubicin hydrochloride
Teva Pharma GmbH
Breast Cancer
1 trial -
Myocet (Non-pegylated liposomal doxorubicin (NPLD))
Sana Biotechnology
Breast Cancer
1 trial -
Palifosfamide Tris and Doxorubicin
Alaunos Therapeutics
Soft Tissue Sarcoma
1 trial -
Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
Bayer HealthCare AG
Carcinoma, Hepatocellular
1 trial -
doxorubicin, docetaxel
Hospital Authority, Hong Kong
Metastatic Breast Cancer
1 trial -
BCA-81472709
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Doxorubicin
United Therapeutics Europe Ltd
Pancreatic Ductal Adenocarcinoma
1 trial -
ZIO-201-T and doxorubicin
Alaunos Therapeutics
Advanced Cancer
1 trial -
Pegylated liposomal doxorubicin
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
SZ5202
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
Liposomal Doxorubicin
United Therapeutics Europe Ltd
Ovarian Cancer
1 trial -
UW 22-704
The University of Hong Kong
Recurrent Ovarian Carcinoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.